S&P/ASX 200 Index (ASX: XJO) shares fell 1.43% to 8,592.9 points yesterday amid no progress on US-Iran negotiations.
Let's check out some new ratings on three ASX shares.
Image source: Getty Images
Southern Cross Gold Consolidated Ltd (ASX: SX2)
This ASX gold share closed at $9.50, down 4.4% yesterday.
The Southern Cross Gold share price has risen by more than 60% over 12 months.
Shaw and Partners has a buy rating on the gold explorer.
The broker gives Southern Cross Gold shares a 12-month price target of $14.40 based on a discounted cash flow (DCF) valuation.
Analyst Alex Barkley said:
Our base case forecasts support our Buy Recommendation, with an implied ~40% stock upside.
We also find substantial project upside potential at Sunday Creek.
Geological extension potential could extend mine life or importantly, allow a larger mining capacity.
Any project expansion returns could be supercharged by the remarkable ~9g/t AuEq site grade.
Key upcoming catalysts include ongoing drilling, an Exploration Target update in Q2 CY26, and a maiden Resource in Q1 CY27.
Centuria Office REIT (ASX: COF)
Centuria Office REIT shares closed steady at 91 cents yesterday.
The ASX real estate investment trust (REIT) has fallen 27% over 12 months.
Bell Potter recently maintained its hold call on this ASX property share and lowered its target from $1.05 to 95 cents.
Analyst Michael Armstrong said:
COF is facing headwinds to earnings from tricky conditions in key exposed markets, rising interest rates, and dilutionary asset divestments.
We forecast earnings declining in FY27 (-2.7% below consensus), holding in FY28, before returning to growth in FY29.
COF screens inexpensive on a P/E and NTA basis but is trading at a P/E to Growth (PEG) ratio of 13.0x, placing it well above peers (sector simple avg. 2.9x).
We see better risk-adjusted opportunities in other sub-sectors at present and believe a pickup in the suburban market is still a little way off.
Healius Ltd (ASX: HLS)
This ASX healthcare share closed steady at 35 cents on Thursday.
The Healius share price has tanked 62% over 12 months.
After the company issued an FY26 earnings downgrade, Jarden kept its sell rating in place.
The broker has a price target of 47 cents, which implies 34% capital growth ahead.
